Defectiveness of bone marrow mesenchymal stem cells in acquired aplastic anemia.
- Author:
Jing-Liao ZHANG
1
;
Xiao-Fan ZHU
Author Information
1. Diagnosis and Treatment Center of Pediatric Blood Diseases, Institute of Hematology and Blood Disease Hospital, Pecking Union Medical College, Chinese Academy of Medical Sciences, Tianjin 300021,China. xfzhu@126.com.
- Publication Type:Journal Article
- MeSH:
Anemia, Aplastic;
etiology;
immunology;
therapy;
Bone Marrow;
Cell Differentiation;
Cell Proliferation;
Cytokines;
analysis;
Humans;
Lymphocyte Activation;
Mesenchymal Stem Cell Transplantation;
Mesenchymal Stromal Cells;
physiology;
T-Lymphocytes, Regulatory;
immunology
- From:
Chinese Journal of Contemporary Pediatrics
2015;17(1):100-106
- CountryChina
- Language:Chinese
-
Abstract:
The defectiveness of bone marrow mesenchymal stem cells (BM-MSCs) in acquired aplastic anemia (AA) has been a frequent research topic in recent years. This review summarizes the defectiveness of BM-MSCs which is responsible for the mechanism of acquired AA and the prospective application of BM-MSCs in the treatment of acquired AA. An increasingly number of laboratory statistics has demonstrated that the defectiveness of BM-MSCs is more likely to play an important role in the pathogenesis of AA, namely, the apparently different biological characteristics and gene expression profiles, the decreased ability of supporting hematopoiesis as well as self-renewal and differentiation, and the exhaustion of regulating immune response of hematopoietic environment. Those abnormalities continuously prompt AA to become irreversible bone marrow failure along with the imbalanced immunity. With deepening research on MSCs, infusion of MSCs for the primary purpose of recovering hematopoietic microenvironment may become a new approach for the treatment of AA.
